In summary, loss of HIF1α in T cells impairs their tumor killing capacity and renders tumor-bearing mice resistant to ICBs, revealing a major T cell-intrinsic mechanism of therapeutic resistance to ICBs, which can be overcome by acetate supplementation (Fig. S7E). The gene discussed is HIF1A; the disease is neoplasm.